• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ZOLL MANUFACTURING CORPORATION LIFEVEST WCD 4000 SYSTEM; WEARABLE CARDIOVERTER DEFIBRILLATOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ZOLL MANUFACTURING CORPORATION LIFEVEST WCD 4000 SYSTEM; WEARABLE CARDIOVERTER DEFIBRILLATOR Back to Search Results
Model Number WCD 4000
Device Problem Signal Artifact/Noise (1036)
Patient Problems Atrial Fibrillation (1729); Bradycardia (1751); Tachycardia (2095); Ventricular Fibrillation (2130); Asystole (4442)
Event Date 01/17/2022
Event Type  Death  
Manufacturer Narrative
The electrode belt and monitor have not been recovered.The device flag data from the last download does not indicate any device malfunction.
 
Event Description
A us distributor contacted zoll to report that a patient passed away in the hospital while wearing the lifevest on (b)(6) 2022.Review of the download data, indicates the patient received 11 appropriate shocks during vf.At 00:10:49, the patient's rhythm was af with rvr at 160 bpm transitioning to vf with motion artifact.Motion artifact prevented the lifevest from treating the patient.At 00:12:13, the patient received the first appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was sinus rhythm at 70 bpm with pvcs.At 00:13:47, the patient received the second appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was sinus tachycardia at 100 bpm with pvcs and pacs degrading back to vf.At 00:15:03, the patient received the third appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was sinus rhythm at 90 bpm with motion artifact and nsvt.At 00:16:31, the patient received the fourth appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was sinus bradycardia at 50 bpm with pvcs and nsvt degrading to vf with motion artifact.At 00:18:09, the patient received the fifth appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was asystole with intermittent cardiac activity.At 00:20:22, the patient received the sixth appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was sinus rhythm at 80 bpm with pvcs and nsvt.At 00:21:53, the patient received the seventh appropriate treatment.The patient's rhythm at the time of the treatment event was vf with motion artifact.The patient's post-shock rhythm was sinus rhythm at 90 bpm with pvcs degrading to vf.At 00:22:38, the patient received the eighth appropriate treatment.The patient's rhythm at the time of the treatment event was vf.The patient's post-shock rhythm was af with rvr at 200 bpm with pvcs degrading to vf.At 00:23:11, the patient received the ninth appropriate treatment.The patient's rhythm at the time of the treatment event was vf.The patient's post-shock rhythm was af at 140 bpm with pvcs and nsvt degrading to vf.At 00:23:57, the patient received the tenth appropriate treatment.The patient's rhythm at the time of the treatment event was vf.The patient's post-shock rhythm was nsvt transitioning to vt at 230 bpm.At 00:24:18, the patient received the eleventh appropriate treatment.The patient's rhythm at the time of the treatment event was vf.The patient's post-shock rhythm was af with rvr at 170 bpm with pvcs and nsvt degrading to vf.The patient passed away on (b)(6) 2022 at approximately 12:30 am.Post-shock asystole is a known and potentially adverse outcome of defibrillation therapy.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LIFEVEST WCD 4000 SYSTEM
Type of Device
WEARABLE CARDIOVERTER DEFIBRILLATOR
Manufacturer (Section D)
ZOLL MANUFACTURING CORPORATION
121 gamma drive
pittsburgh PA 15238 3495
Manufacturer (Section G)
ZOLL MANUFACTURING CORPORATION
121 gamma drive
pittsburgh PA 15238 3495
Manufacturer Contact
steven kyle
121 gamma drive
pittsburgh, PA 15238-3495
4129683333
MDR Report Key13538123
MDR Text Key285663228
Report Number3008642652-2022-01636
Device Sequence Number1
Product Code MVK
UDI-Device Identifier00855778005005
UDI-Public00855778005005
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P010030
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Distributor
Reporter Occupation Other
Type of Report Initial
Report Date 02/14/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/15/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Model NumberWCD 4000
Device Catalogue Number10A0988
Was Device Available for Evaluation? Yes
Date Manufacturer Received01/18/2022
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured05/05/2015
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Death;
-
-